Popular Locations
- Yale New Haven Children's Hospital
- Yale New Haven Hospital - York Street Campus
- Yale New Haven Hospital - Saint Raphael Campus
Thursday, September 2, 2021
Smilow Cancer Hospital at Yale New Haven is part of the nationally recognized Yale New Haven Hospital, and is affiliated with Yale Cancer Center (YCC), one of only 51 National Cancer Institute (NCI)-designated comprehensive cancer centers in the nation and the only such center in Connecticut. Smilow Cancer Hospital, the most comprehensive cancer facility in New England, includes private inpatient rooms, multidisciplinary outpatient treatment centers, 12 operating rooms, infusion suites, diagnostic imaging services, and specialized women's and children’s services. Smilow Cancer Hospital also operates a dozen outpatient care centers across Connecticut. YCC and Smilow Cancer Hospital are members of the National Comprehensive Cancer Network (NCCN), an alliance of 28 cancer centers in the U.S., whose mission is to improve the quality, effectiveness and efficiency of oncology care. www.ynhh.org/smilow.
9/30/2021
Margaret Gilshannon named Deputy Director for Finance & Administration at Yale Cancer CenterNew Haven, CT (September 30, 2021)— Margaret Gilshannon, MHA, has been appointed Deputy Director for Finance & Administration at Yale Cancer Center. Gilshannon joined Yale Cancer Center last year as Senior Director of Finance & Administration, while also leading the Integrated Business Operations for the Department of Pathology at Yale School of Medicine.
9/25/2021
Yale Cancer Center Study Demonstrates Efficacy of Risk Calculator in Treating Geriatric Patients with CancerNew Haven, CT (Sept. 25, 2021) - Yale Cancer Center researchers show using a validated risk calculator helped drive informed treatment decisions in older patients with cancer.
9/17/2021
Yale Cancer Center Study Shows New Drug Combinations Improve Outcomes for Patients with Advanced Lung CancerNew Haven, CT - New findings from a large study led by researchers at Yale Cancer Center shows the addition of the drugs oleclumab or monalizumab to durvalumab improved progression-free survival for patients with locally advanced non-small cell lung cancer (NSCLC).